ARS Pharmaceuticals Stock (NASDAQ:SPRY)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$17.87

52W Range

$8.91 - $18.90

50D Avg

$16.04

200D Avg

$13.88

Market Cap

$1.80B

Avg Vol (3M)

$1.43M

Beta

0.97

Div Yield

-

SPRY Company Profile

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

155

IPO Date

Dec 04, 2020

Website

SPRY Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 24
Product	$7.25M

Fiscal year ends in Dec 24 | Currency in USD

SPRY Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	$89.15M	$30.00K	$1.32M
Operating Income	$-3.08M	$-67.52M	$-35.52M
Net Income	$8.00M	$-54.37M	$-33.99M
EBITDA	$-3.08M	$-67.45M	$-35.52M
Basic EPS	$0.08	$-0.57	$-0.85
Diluted EPS	$0.08	$-0.57	$-0.85

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q1 25May 14, 25 | 8:30 AM

Q4 24Mar 20, 25 | 8:30 AM

Q3 24Nov 13, 24 | 8:00 AM

Peer Comparison

Ticker	Company
TCRX	TScan Therapeutics, Inc.
OCEA	Ocean Biomedical, Inc.
INAB	IN8bio, Inc.
DRMA	Dermata Therapeutics, Inc.
ELEV	Elevation Oncology, Inc.
ZURA	Zura Bio Limited